Clearmind reports mucoadhesion results for intranasal MEAI formulation

Source and reference

reference solution. The formulation incorporates a mucoadhesive polymer system designed to increase residence time at mucosal surfaces. The study was conducted as part of Clearmind’s development program for an intranasal formulation of MEAI. The program aims to improve the residence time of MEAI within the nasal cavity before mucociliary clearance removes the formulation from the nasal surface. Clearmind is a clinical-stage biotechnology company developing treatments for Alcohol Use Disorder, addiction, and weight management. The company’s intellectual portfolio consists of 19 patent families, including 32 granted patents. Shares of Clearmind trade on Nasdaq under the symbol CMND.The company carries a market capitalization of just $2.7 million, with shares currently trading at $1.80, near their 52-week low of $1.82. According to InvestingPro analysis, the stock appears undervalued at...